Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have established that ambulatory treatment of pulmonary tuberculosis with a standard daily regimen of isoniazid plus PAS for one year yields satisfactory results. However, this regimen may be unsuitable for large-scale use in many developing countries, because PAS is expensive, bulky and unpleasant to take, and has poor keeping qualities, especially in tropical countries. It might be possible to overcome these disadvantages, by substituting for the PAS a drug which is equally effective but less expensive and more acceptable, or by reducing the daily dosage of PAS and the period for which it is prescribed. This paper presents the results over a II-month period of a c...
This report from the Tuberculosis Chemotherapy Centre, Madras, summarizes the progress over a 5-yea...
A series of controlled studies carried out at the Tuberculosis Chemotherapy Centre have revealed tha...
INTRODUCTION: Consensus on the best treatment regimens for patients with isoniazid-resistant TB is l...
Recent studies have shown that treatment of pulmonary tuberculosis with isoniazid plus p-aminosalic...
Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have established that ambulator...
A controlled clinical trial was undertaken in 247 patients with newly diagnosed pulmonary tuberculo...
This report from the Tuberculosis Chemotherapy Centre, Madras, describes theprogress, over a 5-year...
A series of studies on the rate of inactivation of isoniazid in Indian patients with pulmonary tube...
The last four decades have seen spectacular developments in the management of pulmonary tuberculosis...
A series of studies on the rate of inactivation of isoniazid in Indian patients with pulmonary tube...
value of a fully supervised twice-weekly regimen of high-dosage isoniazid plus streptomycin in the ...
Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have described a comparison of ...
ATI earlier report from this Centre (Tuber-culosis Chemotherapy Centre, Madras, 1964) showed that a ...
This study from the Tuberculosis Chemotherapy Centre, Madras, summarizes the progress during the se...
Since isoniazid is metabolized in man to several derivatives with little or no specific activity ag...
This report from the Tuberculosis Chemotherapy Centre, Madras, summarizes the progress over a 5-yea...
A series of controlled studies carried out at the Tuberculosis Chemotherapy Centre have revealed tha...
INTRODUCTION: Consensus on the best treatment regimens for patients with isoniazid-resistant TB is l...
Recent studies have shown that treatment of pulmonary tuberculosis with isoniazid plus p-aminosalic...
Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have established that ambulator...
A controlled clinical trial was undertaken in 247 patients with newly diagnosed pulmonary tuberculo...
This report from the Tuberculosis Chemotherapy Centre, Madras, describes theprogress, over a 5-year...
A series of studies on the rate of inactivation of isoniazid in Indian patients with pulmonary tube...
The last four decades have seen spectacular developments in the management of pulmonary tuberculosis...
A series of studies on the rate of inactivation of isoniazid in Indian patients with pulmonary tube...
value of a fully supervised twice-weekly regimen of high-dosage isoniazid plus streptomycin in the ...
Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have described a comparison of ...
ATI earlier report from this Centre (Tuber-culosis Chemotherapy Centre, Madras, 1964) showed that a ...
This study from the Tuberculosis Chemotherapy Centre, Madras, summarizes the progress during the se...
Since isoniazid is metabolized in man to several derivatives with little or no specific activity ag...
This report from the Tuberculosis Chemotherapy Centre, Madras, summarizes the progress over a 5-yea...
A series of controlled studies carried out at the Tuberculosis Chemotherapy Centre have revealed tha...
INTRODUCTION: Consensus on the best treatment regimens for patients with isoniazid-resistant TB is l...